HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Researchers Seek Commercial Partner For Nasal Spray Shown To ‘Prevent’ COVID-19

Executive Summary

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

You may also be interested in...



France Puts The Brakes On Launch Of Anti-COVID Nasal Spray

COV-Defense nasal spray, claimed to inactivate the SARS-CoV-2 virus, will no longer launch in France after regulator ANSM demanded rigorous efficacy and safety data.

Risking FTC Scrutiny, Direct Seller Ignores Industry Self-Regulation Group On COVID-19 Claims

Direct seller Flavon USA is referred to FTC after it failed to respond to repeated outreach by Direct Selling Self-Regulatory Council over claims its supplements treat coronavirus. The watchdog asked for substantiation of claims suggesting products also could tumors and diabetes.

Bausch Considers Proposal For COVID-19 Drug: Lumify Eye Drops Inactivate Virus In Lab Tests

Bausch Health says its Lumify OTC redness reliever drops showed "complete inactivation" of COVID-19 in time-kill tests, with preservative compound benzalkonium chloride apparently the key reason. The in vitro findings prompted it to consider discussions with regulatory agencies on proposing a remedy for the virus.

Related Content

Topics

UsernamePublicRestriction

Register

RS150732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel